Literature DB >> 385767

Bacteriostasis of Escherichia coli by milk. IV. The bacteriostatic antibody of human milk.

J M Dolby, P Honour.   

Abstract

Bacteriostatic activity for milk-sensitive and milk-resistant strains of Escherichia coli is reduced when IgA is removed from milk by precipitation. Lysozyme is not involved in bacteriostasis and can be removed without loss of activity; heavy bentonite absorption however removes some lactoferrin causing partial loss of activity. The heat-labile antigen eliciting bacteriostatic antibody for E. coli is present in milk-sensitive and milk-resistant strains and in some other Enterobacteriaceae, e.g. salmonella; it cross reacts with the antigen in others, e.g. proteus and enterobacter. The antibody is therefore likely to be present in all human milk as a result of the normal commensal gut flora and with widespread activity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 385767      PMCID: PMC2129902          DOI: 10.1017/s0022172400026048

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  14 in total

1.  In vitro studies on the antimicrobial effects of colostrum and milk from vaccinated and unvaccinated pigs on Escherichia coli.

Authors:  L K Nagy; T Mackenzie; Z Bharucha
Journal:  Res Vet Sci       Date:  1976-09       Impact factor: 2.534

2.  Bacteriostasis of a milk-sensitive strain of Escherichia coli by immunoglobulins and iron-binding proteins in association.

Authors:  G Spik; A Cheron; J Montreuil; J M Dolby
Journal:  Immunology       Date:  1978-10       Impact factor: 7.397

3.  Antibody production by the mammary gland in mothers after artificial oral colonisation of their infants with a non-pathogenic strain E. coli 083.

Authors:  R Lodinová; V Jouja
Journal:  Acta Paediatr Scand       Date:  1977-11

4.  Bacteriostasis of Escherichia coli by milk. I. Colonization of breast-fed infants by milk resistant organisms.

Authors:  J M Dolby; P Honour; H B Valman
Journal:  J Hyg (Lond)       Date:  1977-02

5.  Bacteriostasis of Escherichia coli by milk. II. Effect of bicarbonate and transferrin on the activity of infant feeds.

Authors:  J M Dolby; S Stephens; P Honour
Journal:  J Hyg (Lond)       Date:  1977-04

6.  Enterobacterial chelators of iron: their occurrence, detection, and relation to pathogenicity.

Authors:  A A Miles; P L Khimji
Journal:  J Med Microbiol       Date:  1975-11       Impact factor: 2.472

7.  IgG diphtheria antitoxin responses from human tonsil lymphocytes induced by anti-gamma-chain antibodies.

Authors:  T A Platts-Mills; K Ishizaka
Journal:  J Immunol       Date:  1975-05       Impact factor: 5.422

Review 8.  Esch. coli infections in childhood. Significance of bacterial virulence and immune defence.

Authors:  L A Hanson
Journal:  Arch Dis Child       Date:  1976-10       Impact factor: 3.791

9.  Bacteriostasis of Escherichia coli by milk. III. The activity and stability of early, transitional and mature human milk collected locally.

Authors:  P Honour; J M Dolby
Journal:  J Hyg (Lond)       Date:  1979-10

10.  Bacteriostatic effect of human milk on Escherichia coli: the role of IgA.

Authors:  H J Rogers; C Synge
Journal:  Immunology       Date:  1978-01       Impact factor: 7.397

View more
  3 in total

1.  Bacteriostasis of Escherichia coli by milk. V. The bacteriostatic properties of milk of West African mothers in the Gambia: in-vitro studies.

Authors:  J M Dolby; P Honour; M G Rowland
Journal:  J Hyg (Lond)       Date:  1980-12

2.  Differences in inhibition of the growth of commensal and enteropathogenic strains of Escherichia coli by lactotransferrin and secretory immunoglobulin A isolated from human milk.

Authors:  S Stephens; J M Dolby; J Montreuil; G Spik
Journal:  Immunology       Date:  1980-11       Impact factor: 7.397

3.  Role of antibody and enterobactin in controlling growth of Escherichia coli in human milk and acquisition of lactoferrin- and transferrin-bound iron by Escherichia coli.

Authors:  J H Brock; M G Pickering; M C McDowall; A G Deacon
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.